美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%

智通财经
Aug 10

智通财经APP获悉,周一,福泰制药(VRTX.US)早盘涨近7%,创历史新高;而竞争对手Sionna Therapeutics(SION.US)暴跌超90%,创记录新低。消息面上,SION表示,由于SION-719实验性囊性纤维化药物在中期临床试验中未能达到主要目标,公司将终止该药物的研发。投资者此前一直担忧SION可能对VRTX的核心囊性纤维化业务构成威胁,但此次试验失败消除了这一担忧。

VRTX公司销售的Trikafta和Alyftrek用于治疗囊性纤维化——这是一种罕见、慢性且会缩短寿命的遗传性疾病,会导致肺部进行性损伤。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10